Clinical Trial Update: A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] [Phase 3]

View source ↗

Summary

A Phase 3 follow-on safety study for CDP870 in Crohn's disease patients who completed prior trials has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CDP870 (certolizumab pegol)

Snippet

Sponsor: UCB Pharma SA | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-10-10